Risk of ovarian failure and fertility after intravenous cyclophosphamide. A study in 84 patients

Journal of Rheumatology

Volumn 29, Issue 12, 2002, Pages 2571-2576

  Huong, Du Le Thi ^a   Amoura, Zahir ^a   Duhaut, Pierre ^a   Sbai, Abdallah ^a   Costedoat, Nathalie ^a   Wechsler, Bertrand ^a   Piette, Jean Charles ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Cyclophosphamide; Ovarian failure; Pregnancy; Systemic lupus erythematosus; Systemic vasculitis

Indexed keywords

CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; ANTIRHEUMATIC AGENT;

ADOLESCENT; ADULT; AMENORRHEA; ARTICLE; CLINICAL TRIAL; FEMALE; FEMALE FERTILITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; OVARY INSUFFICIENCY; PREGNANCY COMPLICATION; PREGNANCY RATE; PRIORITY JOURNAL; RELAPSE; RHEUMATIC DISEASE; SPONTANEOUS ABORTION; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME; VASCULITIS; WEGENER GRANULOMATOSIS; CHEMICALLY INDUCED DISORDER; CHILD; COMPARATIVE STUDY; DRUG EFFECT; FERTILITY; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; OVARY; PHYSIOLOGY; PREMATURE OVARIAN FAILURE; PREMENOPAUSE; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; AMENORRHEA; ANTIRHEUMATIC AGENTS; CHILD; CYCLOPHOSPHAMIDE; FEMALE; FERTILITY; HUMANS; INJECTIONS, INTRAVENOUS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; OVARIAN FAILURE, PREMATURE; OVARY; PREMENOPAUSE; RETROSPECTIVE STUDIES;

EID: 0036894860     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. McDermott EM, Powell RJ. Incidence of ovarian failure in systemic lupus erythematosus after treatment with pulse cyclophosphamide. Ann Rheum Dis 1996;55:224-9.
2. Mok CC, Lau CS, Woon Sing Wong R. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy. Arthritis Rheum 1998;41:831-7.
3. Boumpas DT, Austin HA, Vaughn EM, Yarboro CH, Klippel JH, Balow JE. Risk of sustained amenorrhoea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 1993;119:366-9.
4. Langevitz P, Klein L, Pras M, Many A. The effect of cyclophosphamide pulses on fertility in patients with lupus nephritis. Am J Reprod Immunol 1992;28:157-8.
5. Guillevin L, Jarousse B, Lok C, et al. Longterm followup after treatment of polyarteritis nodosa and Churg Strauss angiitis with comparison of steroids, plasma exchange and cyclophosphamide to steroids and plasma exchange. A prospective randomized trial of 71 patients. J Rheumatol 1991;18:567-74.
6. Haubitz M, Schellong S, Gobel U, et al. Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: A prospective, randomized study. Arthritis Rheum 1998;41:1835-44.
7. Guillevin L, Cordier JF, Lhote F. et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum 1997;40:2187-98.
8. Falsetti L, Scalchi S, Villani MT, Bugari G. Premature ovarian failure. Gynecol Endocrinol 1999;13:189-95.
9. Pasoto SG, Viana BST, Mendonca BB, Yoshinari NH, Bonfa H. Anti-corpus luteum antibody: A novel serological marker for ovarian dysfunction in systemic lupus erythematosus? J Rheumatol 1999;26:1087-93.
10. Chapman RM, Sutcliffe SB. Protection of ovarian function by oral contraceptives in women receiving chemotherapy for Hodgkin's disease. Blood 1981;58:849-51.
11. Jungers P, Dougados M, Pelissier C, et al. Influence of oral contraceptive therapy on the activity of systemic lupus erythematosus. Arthritis Rheum 1982;25:618-23.
12. Sanchez-Guerrero J, Karlson EW, Liang MH, Hunter DJ, Speizer FE, Colditz GA. Past use of oral contraceptives and the risk of developing systemic lupus erythematosus. Arthritis Rheum 1997;40:804-8.
13. Blumenfeld Z, Shapiro D, Shteinberg M, Avivi I, Nahir M. Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated with chemotherapy. Lupus 2000;9:401-5.
14. Cruz OVP, Ariza R, Banuelos R, Jara LJ, Miranda JM. Ovarian function preservation with chlormadinone in lupus patients receiving cyclophosphamide. A double-blind controlled study [abstract]. Arthritis Rheum 1999;42 Suppl:S166.
15. Enns GM, Roeder E, Chan RT, Ali-Khan Catts Z, Cox VA, Golabi M. Apparent cyclophosphamide (Cytoxan) embryopathy: A distinct phenotype? Am J Genet 1999;86:237-41.
16. Matsukawa Y. Successful child bearing during intravenous cyclophosphamide therapy in a patient with systemic lupus erythematosus. Br J Rheumatol 1997;37:342-3.
17. Kirshon B, Wasserstrum N, Willis R, Herman GE, McCabe ERB. Teratogenic effects of first-trimester cyclophosphamide therapy. Obstet Gynecol 1988;72:462-4.
18. Nguyen Tan Lung R, Cranier M, Gaudry C, Kourilsky O. Cyclophosphamide during pregnancy: A safe prescription [in French]. J Gyn Obstet Biol Reprod 1995;24:314-8.
19. Talbot SF, Main DM, Levinson AI. Wegener's granulomatosis: First report of a case with onset during pregnancy. Arthritis Rheum 1984;27:109-12.
20. Fields CL, Ossorio MA, Roy TM, Bunke CM. Wegener's granulomatosis complicated by pregnancy. A case report. J Reprod Med 1991;36:463-6.
21. Luisiri P, Lance NJ, Curan JJ. Wegener's granulomatosis in pregnancy. Arthritis Rheum 1997;40:1354-60.
22. Ramsey-Goldman R, Mientus JM, Kutzer JE, Mulvihill JJ, Medsger TA. Pregnancy outcome in women with systemic lupus erythematosus treated with immunosuppressive drugs. J Rheumatol 1993;20:1152-7.